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This study examined the potential benefits of malaria in pregnancy (MiP) preventive strategies 23 
in infants and showed, that enhanced screening and treatment, in addition to standard IPTp-SP, 24 
may provide additional protection against malaria and non-malaria fevers in early infancy. 25 
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Abstract  29 
Background: Although consensus on that malaria in pregnancy (MiP) increases the risk of malaria 30 
in infancy, and eventually non-malaria fevers (NMFs), there is a lack of conclusive evidences of 31 
benefits of MiP preventive strategies in infants. 32 
Methods: In Burkina Faso, a birth cohort study was nested to a clinical trial assessing the 33 
effectiveness of a community-based scheduled screening and treatment of malaria in combination 34 
with intermittent preventive treatment with sulfadoxine-pyrimethamine (CSST/IPTp-SP) to 35 
prevent placental malaria. Clinical episodes and asymptomatic infections were monitored over one-36 
year follow-up to compare the effect of CSST/IPTp-SP and standard IPTp-SP on malaria and 37 
NMFs. 38 
Results: Infants born during low-transmission season from mothers receiving CSST/IPTp-SP had 39 
a 26% decreased risk of experiencing a first clinical episode (HR, 0.74 [95% CI, 0.55- 0.99]; P = 40 
.047). CSST/IPTp-SP interacted with birth season and gravidity to reduce the incidence of NMFs. 41 
No significant effects of CSST/IPTp-SP on the incidence of clinical episodes, parasite density and 42 
Plasmodium falciparum infections were observed.  43 
Conclusions: Our findings indicate that CSST/IPTp-SP strategy may provide additional protection 44 
against both malaria and NMFs in infants during the first year of life, and suggest that malaria 45 
control interventions during pregnancy could have long-term benefits in infants.  46 
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 49 
Introduction 50 
Malaria in pregnancy (MiP) causes significant adverse health effects in both mothers and their 51 
newborn children and, is estimated to account for between 75000 and 200000 infant deaths a 52 
year[1]. While maternal mortality is often associated with severe maternal anaemia, infant deaths 53 
are due to complications during pregnancy, such as foetal growth restriction, foetal anaemia, pre-54 
term deliveries and congenital malaria [1]. 55 
 56 
The hallmark of MiP due to Plasmodium falciparum is placental malaria (PM), characterized by 57 
sequestration of infected erythrocytes in intervillous spaces of the placenta through binding to 58 
chondroitin sulfate A on syncytiotrophoblast [2]. Increasing evidence from birth cohort studies 59 
have shown that PM is associated with increased susceptibility to malaria during infancy [3–8], 60 
probably due to the acquisition of immune tolerance to parasite antigens during in utero exposure. 61 
Likewise, the development of a tolerogenic environment as a result of PM might also be the cause 62 
for increased infant-susceptibility to non-malaria fevers (NMFs) [9]. 63 
 64 
Intermittent preventive treatment with at least three full sulfadoxine-pyrimethamine (IPTp-SP) 65 
doses (administered at least one month apart), combined with the use of insecticide treated bed-66 
nets (ITNs), is currently the recommended strategy for preventing MiP in most malaria endemic 67 
countries, as it reduces the risk of PM at delivery, neonatal mortality and infants’ low birth weight 68 
(LBW) [10]. However, the effectiveness of this IPTp-SP based intervention is threatened by the 69 
growing spread of parasites with increasing resistance to SP [11]. In this context, studies assessing 70 
 4 
the impact of novel anti-malarial interventions during pregnancy, not only on pregnant women but 71 
also on their infants, are urgently needed as information to date is scarce and inconclusive [12,13].  72 
 73 
A multicentre cluster-randomized controlled trial (COSMIC) was recently conducted in three west-74 
African countries with high (Burkina Faso and Benin) and low (The Gambia) malaria transmission, 75 
to assess the protective efficacy of adding community-scheduled screening and treatment of 76 
malaria during pregnancy (CSST) to standard IPTp-SP (CSST/IPTp-SP). The CSST extension 77 
strategy was implemented monthly by community health workers using rapid diagnostic test 78 
(RDT). The aim of the combined CSST/IPTp-SP strategy was to provide additional opportunities 79 
to detect and treat malaria infections during pregnancy and reduce the prevalence of PM [14]. 80 
In this study, we have followed infants born to mothers at the Burkina Faso site in the COSMIC 81 
trial, with the aim to evaluate whether CSST/IPTp-SP compared to IPTp-SP alone was effective in 82 
protecting infants from malaria and NMFs during the first year of life.  83 
 84 
Material and methods  85 
Study site 86 
The study was conducted in Nanoro, a rural area with high malaria transmission located in the 87 
central-west region of Burkina Faso. Malaria transmission occurs year-round and is highly 88 
seasonal. Transmission peaks between July and December overlapping with the rainy season (July 89 
to November). P. falciparum is the main species responsible for transmission, with a prevalence of 90 
90%. The prevalence of peripheral and placental P. falciparum infections at delivery during the 91 
high-transmission season is estimated at 32% and 34% respectively [15]. In 2015, approximately 92 
7.4 million of clinical malaria cases and 32000 malaria related deaths were recorded in Burkina 93 
Faso [16]. Out of 91154 clinical malaria episodes that occurred in Nanoro health district in 2016, 94 
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approximately 55% were detected among infants below five years of age [17].  95 
 96 
Study design and participants 97 
This was an observational birth cohort study of infants born to women who participated in the 98 
COSMIC trial (NCT01941264), described in detail elsewhere [14]. In COSMIC trial it was 99 
assumed that CSST/IPTp-SP strategy would decrease PM by 30%. Following this assumption, and 100 
considering the prevalence of malaria infection in a 12-month birth cohort study in Benin (35%) 101 
[4], as at the time of recruitment there were no such data available in Burkina Faso, we assumed 102 
that the impact of the intervention will decrease P. falciparum infection during the first year of life 103 
by 30%, from 35% to 25%. With a 1:1 ratio to provide a power of at least 80% with 5% precision, 104 
the required sample size was estimated to 350 newborns in each study arm. To account for loss to 105 
follow-up and exclusion criteria at delivery, a total of 752 pregnant women from COSMIC trial 106 
(376 in each arm) were enrolled between March 2014 and June 2015 onto the current study. Written 107 
informed consent was obtained from all mothers and ethical approval was obtained from the 108 
institutional ethics committees of Centre Muraz, Bobo Dioulasso, Burkina Faso (006-2014/CE-109 
CM), the Institute of Tropical Medicine, Antwerp, Belgium (953/14) and University Hospital in 110 
Antwerp (UZA), Belgium (14/26/277).  111 
 112 
Recruitment and follow-up procedures 113 
Pregnant women participating in the COSMIC trial were invited to participate in the present study 114 
at any antenatal care visits but the enrollment of mother-child pairs onto this study occurred at time 115 
of delivery. Exclusion criteria at time of delivery were maternal death, stillbirth and presence of 116 
major congenital malformation, chronic diseases or signs of cerebral asphyxia.  Maternal peripheral 117 
blood was collected by finger-prick to prepare blood smears and blood spots on filter paper for 118 
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subsequent malaria diagnosis. A tissue section was collected from the maternal side of the placenta 119 
and preserved into 10% neutral buffered formalin at 4°C for histological examination within the 120 
COSMIC trial. A drop of placental blood was also spotted on filter paper. Infants were followed 121 
for 12 months and malaria infections were detected actively and passively. Active case detection 122 
consisted of four cross-sectional surveys conducted at 3, 6, 9 and 12 months of age. For each 123 
survey, blood films and blood spots on filter papers were collected for examination by light 124 
microscopy (LM) and quantitative real-time polymerase chain reaction (qPCR), respectively. For 125 
passive clinical case detection, mothers were encouraged to bring their offspring to the health 126 
centre if they displayed any signs of illness. Infants presenting with fever (axillary temperature 127 
≥37.5ºC) on examination or a history of fever in the previous 24 hours, were screened for malaria 128 
infection using RDT (SD-Bioline Malaria Ag P.f, Standard Diagnostic, Inc, Korea) and, if 129 
positive, treated according to national guidelines. Malaria diagnosis was subsequently confirmed 130 
by LM and qPCR.  131 
 132 
Laboratory methods 133 
LM readings were taken according to standard procedures by two independent experienced readers 134 
[18]. A third reader was consulted in cases of discrepancies. Dried blood spots on filter papers were 135 
used for DNA extraction (QIAamp 96 DNA blood kit, Qiagen, Germany) and, P. falciparum 136 
detection and quantification by Pf-varATS qPCR using procedures described elsewhere [15]. The 137 
limit of detection of the Pf-vasATS qPCR was estimated at 0.1 parasite/µL and qPCR was used as 138 
reference malaria diagnostic test. Data on past history of malaria infections during pregnancy and 139 
histological examinations of placental tissue data were obtained from the COSMIC trial [14]. 140 
 141 
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Data analysis and definition of terms 142 
Data were double entered into the study databases (OpenClinica, community version or Excel, 143 
Microsoft, USA) and analyzed with STATA 12.0 (StataCorp, USA). The baseline characteristics 144 
of mother-child pairs were compared between the study arms. Continuous data normally distributed 145 
and categorical variables were analyzed using the t-test and the χ2 test, respectively. Non-normally 146 
distributed data were described using median and interquartile ranges (IQR).  147 
The risk of malaria and NMFs during the first year of life was analyzed using the following 148 
outcomes: time from birth to the first clinical malaria episode, incidence of clinical malaria 149 
episodes, parasite density, prevalence of P. falciparum infection and incidence of NMFs. The main 150 
exposure was the MiP intervention (CSST/IPTp-SP or IPTp-SP). The effect of prenatal malaria 151 
exposure -defined as maternal peripheral and placental infections- on outcome was investigated in 152 
a separate analysis. Maternal age, gravidity, ITN usage by mothers, birth season and newborn sex 153 
were considered as potential confounders. Twin infants were excluded from the analysis.  154 
The effect of the interventions on time-to-first clinical malaria episode was analyzed using Cox 155 
proportional univariate and multivariate analyses, while Kaplan-Meier analysis was used to 156 
calculate the survival curves. Because MiP preventive strategies may have a causal effect on 157 
pregnancy outcomes and subsequently an effect on the risk of malaria in infancy, neither low birth 158 
weight (LBW) nor maternal peripheral and PM infections at delivery were used as covariates in 159 
the multivariate Cox proportional models. The effect of the interventions on the incidence of 160 
clinical malaria episodes and NMFs was investigated using Poisson regression or negative binomial 161 
models depending on the goodness-of-fit tests with results expressed as incidence rate ratios (IRRs 162 
with 95% confidence interval (CI)). Linear regression analysis was used for log-transformed 163 
parasite densities and logistic regression models for P. falciparum infection excluding censored 164 
infants. Variables with a P value < .1 in univariate analyses were included in multivariable 165 
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analyses. A P value < .05 was considered to be statistically significant. The definitions of terms 166 
and the different categories of prenatal malaria exposure used in the present study are shown in 167 
Supplementary Table 1.  168 
 169 
Results  170 
 171 
Study population 172 
The flow chart of the birth cohort study is shown in Figure 1. Out of the 761 infants (from 752 173 
mothers) enrolled in the study, 669 (88%) completed the 12-months follow-up. Of the remaining 174 
92 infants, 41 were lost to follow-up, 38 had consent withdrawn mainly because of migration from 175 
the study area and 13 died (seven neonatal deaths and six within 1 to 12 months). In total, 734 of 176 
the initial 761 infants were included in the survival analysis (367 in each COSMIC study arm). The 177 
infants excluded from the analysis were the seven neonates who died before four weeks of age and 178 
the 20 live twins although they completed follow-up. The cross-sectional surveys conducted at 3, 179 
6, 9 and 12 months of age included 678 (92.4%), 631 (86%), 587 (80%) and 638 (86.9%) infants 180 
respectively. Table 1 presents the characteristics of the mothers and infants as a whole and by MiP 181 
intervention group. The baseline maternal and infant demographic and parasitological 182 
characteristics were similar between the participants in the CSST/IPTp-SP and standard IPTp-SP 183 
arms. 184 
 185 
Malaria infections 186 
Overall incidence of clinical malaria in the study population was 1.03 episodes per child-year (a 187 
total of 717 cases over 8335.18 months at risk) and the median survival time from birth to the first 188 
clinical malaria episode was 9.9 months. Nearly 59% (433/734) of the infants experienced at least 189 
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one clinical malaria episode during the first 12 months of life. The prevalence of asymptomatic 190 
infections as detected by qPCR in the cross-sectional surveys was 17.70% (120/678) at 3 months, 191 
20.13 (127/631) at 6 months, 18.40 (108/587) at 9 months and 30.41% (194/638) at 12 months. 192 
Median qPCR-parasite density during clinical malaria episodes (10826.50 [IQR 876.50-38021.50] 193 
parasites/µL) was significantly higher than that during asymptomatic infections  (379 [IQR 1.94-194 
3932.5] parasites/µL, P < .0001). 195 
 196 
Effect of CSST/IPTp-SP strategy on time-to-first clinical malaria episode 197 
Although time-to-first clinical malaria episode was not significantly different between the two 198 
study arms in univariate and multivariate analyses (Table 2), birth season was found to interact and 199 
significantly modify the effect of CSST/IPTp-SP on time-to-first clinical malaria episodes. We 200 
observed that infants born to mothers in the CSST/IPTp-SP arm during malaria low-transmission 201 
season had a 26% decreased risk of a first clinical malaria episode compared with those born to 202 
mothers in the IPTp-SP arm (HR, 0.74 [95% CI, 0.55-0.99]; P = .047). By contrast, no significant 203 
differences were observed between the two arms for infants born during malaria high-transmission 204 
season (HR, 0.97 [95% CI, 0.76-1.25]; P = .846). That difference of the effect of CSST/IPTp-SP 205 
on time-to-first clinical malaria episode according to birth season was further illustrated in Kaplan-206 
Meier survival curves (Figure 2).  207 
We investigated whether the observed effect of CSST/IPTp-SP could be explained by differences 208 
in prenatal malaria exposure. Table 3 shows that the increased risk of time-to-first clinical malaria 209 
episode was associated with peripheral infection during pregnancy and past PM  (P = .009 and P 210 
= .020, respectively) but not with active PM (P = .177), after adjusting by gravidity, birth season 211 
and LBW. Thus, the effect of CSST/IPTp-SP on time-to-first clinical malaria episode was more 212 
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likely to be attributable to the impact on malaria infection during pregnancy rather than to active 213 
PM. 214 
The two COSMIC study arms had a similar effect on infant parasite density during the first clinical 215 
malaria episode (6557.50 [IQR, 609.00-28484.50] parasites/µL in CSST/IPTp-SP vs. 4549.00 216 
[IQR, 380.50-19627.75] parasites/µL in standard IPTp-SP). Similar lack of association was 217 
observed on parasitaemia in all clinical episodes even after adjusting for gravidity and sex 218 
(coefficient, 1.10 [95% CI, 0.82-1.47]; P = .526) (Supplementary Table 2). 219 
 220 
Effect of CSST/IPTp-SP strategy on the incidence of clinical malaria episodes 221 
Table 4 shows results of the analysis of the effect of the CSST/IPTp-SP strategy on the incidence 222 
of clinical malaria episodes including repeated malaria attacks per infant during the first year of 223 
life. We found no significant differences between CSST/IPTp-SP and IPTp-SP after adjusting for 224 
birth season (adjusted IRR, 0.95 [95% CI, 0.82-1.10]; P = .459). Moreover, no significant 225 
differences were observed in the stratified analysis by birth season (high-transmission season: IRR, 226 
0.99 [95% CI, 0.82-1.20]; P = .941; low-transmission season IRR, 0.91 [95% CI, 0.72-1.14]; P = 227 
.409). 228 
 229 
Effect of CSST/IPTp-SP strategy on P. falciparum infections 230 
In total, 553 of 690 infants (80.14%) experienced at least one symptomatic or asymptomatic 231 
infection during the first year of life. The odds of experiencing a P. falciparum infection in infants 232 
born to mothers in the CSST/IPTp-SP group was not significantly different from that of children 233 
born to mothers in the IPTp-SP group, even after controlling for gravidity (adjusted OR, 1.20 [95% 234 
CI, 0.82-1.74]; P = .348) (Supplementary Table 3). There were also no statistical differences 235 
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between the groups in terms of the proportions of asymptomatic infections in infants, regardless of 236 
the time of screening (Supplementary Table 4).  237 
 238 
Effect of CSST/IPTp-SP strategy on the incidence of NMFs  239 
A total of 805 NMFs episodes (incidence, 1.16 per child-year) were recorded in the 734 infants 240 
analyzed during their first year of life. Table 5 presents the stratified analysis by birth season and 241 
gravidity that were found to interact with CSST/IPTp-SP strategy to modify infant’s susceptibility 242 
to NMFs. Infants born to CSST/IPTp-SP mothers during malaria high-transmission season had a 243 
significantly lower risk of developing NMFs than their counterpart born to mothers receiving the 244 
standard IPTp-SP (adjusted IRR, .79 [95% CI, 0.64-0.98]; P = .031) (Table 5). When stratifying 245 
the analysis by gravidity, only the offspring of multigravid women in the CSST/IPTp-SP group 246 
were significantly protected against NMFs (adjusted IRR, .78 [95% CI, 0.63-0.97]; P = .027). We 247 
did not observe any significant associations between prenatal malaria exposure and occurrence of 248 
NMFs (Supplementary Table 5).  249 
 250 
Discussion  251 
In this prospective birth cohort study we found that, compared with standard IPTp-SP strategy, 252 
CSST/IPTp-SP significantly increased time-to-first clinical malaria episode in infants born during 253 
malaria low-transmission season, and protected against the occurrence of NMFs in those born 254 
during malaria high-transmission season. Due to the transmission seasonality of malaria and NMFs 255 
in Burkina Faso, CSST/IPTp-SP strategy appears to have different impact in women who had the 256 
main course of their pregnancy during malaria high-transmission season (and most probably gave 257 
birth during malaria low-transmission season) compared to those who were pregnant during 258 
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malaria low-transmission season (and most probably gave birth during malaria high-transmission 259 
season).  260 
 261 
Our findings showed, for the first time, that MiP preventive treatments may provide protection 262 
against malaria in infants during the first year of life, in addition to the known protection against 263 
adverse pregnancy outcomes. New MiP strategies should thus be evaluated not only for the 264 
protective effect on pregnancy outcomes but also the potential additional long-term benefits in 265 
infants. To our knowledge, only one study has compared the incidence of malaria in infants born 266 
to mothers who received either IPTp-SP or screening and treatment with RDT and artemether-267 
lumefantrine (ISTp-AL) during antenatal care visits, without IPTp-SP [13]. The authors found no 268 
differences in the risk of clinical malaria episodes during early life and observed that the two 269 
interventions had similar performance in preventing PM [13]. In comparison, the strategy of 270 
combining a CSST with the standard IPTp-SP increases the chances of clearing parasite infections 271 
when the protective efficacy of IPTp-SP is waned, thus reducing the risk of long-term parasite 272 
carriage during pregnancy. Indeed, thanks to the enhanced screening, the proportion of malaria 273 
infections detected by RDT amongst women in the CSST/IPTp-SP arm was significantly higher 274 
than that among women in the routine IPTp-SP arm (Table 1). 275 
 276 
Remarkably, the impact of the CSST/IPTp-SP strategy on the risk of malaria in infancy was evident 277 
in infants born to women who had the main course of their pregnancy during malaria high-278 
transmission season (and thus born during low-transmission season), while the two interventions 279 
performed similarly when the main course of pregnancy was during the low-transmission season. 280 
Therefore, we hypothesized that this effect of CSST/IPTp-SP is attributable to the additional 281 
reduction in parasite exposure that was not prevented by the standard IPTp-SP owing to the fact 282 
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that maternal peripheral infections were associated with an increased risk of malaria in infants 283 
(Table 3). The observation that past PM and peripheral infections during pregnancy, but not active 284 
PM, were associated with a risk of clinical malaria suggests that preventing infections at early stage 285 
of pregnancy may have a critical effect on future infant susceptibility. Most studies to date have 286 
focused in looking at the association between PM and malaria risk, probably thus missing the 287 
overall effect of preventing all infections [3–8]. Our findings are supported by a recent study that 288 
showed that the timing of prenatal malaria exposure had a pivotal role on the polarization of the 289 
foetal immune responses [19]. In this context, the study that we are currently conducting on the 290 
relationships between types of prenatal malaria exposure, innate immune responses at birth and the 291 
subsequent risk of malaria in early infancy will provide further understanding on how maternal 292 
infections modulate newborn’s immune responses and affect risk of malaria during the first year 293 
of life.  294 
CSST/IPTp-SP strategy significantly increased time from birth to the first clinical malaria episode 295 
compared with the standard IPTp-SP in infants born during the low transmission season, 296 
however this effect did not translate into a significant reduction of malria incidence in the 297 
same group. Although the difference was non-significant, the overall clinical malaria incidence 298 
was also reduced in these infants  suggesting that a MiP intervention with a stronger effect size 299 
on time to first infection would further reduce malaria incidence in infancy. In this study, the 300 
observed effect of the CSST/IPTp-SP intervention may have been limited by the sensitivity of the 301 
RDT used during screenings (limit of detection of approximately 200 parasites/µL) [20]. It is thus 302 
reasonable to assume that the lack of effect observed in infants born to mothers who were mostly 303 
pregnant during the low-transmission season might be due to the reduction of transmission intensity 304 
during this time and to the possibility that RDTs might have missed a considerable proportion of 305 
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low-density infections [21]. We are tempted to speculate that the effect of the CSST/IPTp-SP 306 
intervention could be increased with the use of high-sensitivity diagnostic tools capable of 307 
detecting low-density infections. In this regard, high-sensitivity RDTs currently used in field 308 
testing (PATH) [22] and molecular strategies such as LAMP [23], which have a limit of detection 309 
of 10-20 parasites/µl and < 1 parasite/µL respectively, are promising tools to improve screening 310 
strategies. 311 
 312 
It is noteworthy that the CSST/IPTp-SP intervention was also associated with a reduced incidence 313 
of NMFs during the first year of life in infants born during malaria high-transmission season but 314 
not in those born during malaria low-transmission season. Therefore, it is unlikely that the same 315 
mechanism underlies the susceptibility to NMF since this protection, which is in agreement with a 316 
previous study [24], was independent of PM, even after exploring the association with different 317 
categories of prenatal malaria exposure. Nevertheless, several studies have reported modulation of 318 
the foetal immune system by malaria infections during pregnancy [19,25,26]. In addition to 319 
malaria-specific immune responses, these modifications may also affect specific immunity to other 320 
pathogens responsible of NMFs [27,28], such as those caused by blood stream infections, 321 
gastrointestinal infections, acute respiratory infections, urinary tract infections and arbovirus 322 
infections  [29,30].  323 
Moreover, the CSST/IPT-SP intervention was found to interact with gravidity to significantly 324 
protect infants born to multigravid women but not these born to either secundigravid (non-325 
significant protection) or primigravid women (non-significant increased risk). These findings 326 
suggest that, through the modification of prenatal malaria exposure (which may differ 327 
depending on gravidity), the CSST/IPTp-SP intervention alters or prime the development of 328 
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fetal immune system affecting immunity to pathogens that are responsible of NMFs in early 329 
infancy. To gain further an understanding of how MiP preventive interventions can modulate the 330 
immune system to impact infant susceptibility to NMFs, new studies should include diagnosis of 331 
NMFs.  332 
 333 
Conclusion  334 
In this study we have shown that, compared with standard IPTp-SP, CSST/IPTp-SP significantly 335 
decreases the risk of experiencing a first clinical malaria episode and also interact with birth season 336 
and gravidity to reduce the incidence of NMFs during the first year of life. Altogether, our findings 337 
suggest that MiP preventive strategies that effectively reduce exposure to malaria parasites during 338 
pregnancy could provide additional protection against both malaria and NMFs in early infancy and 339 
therefore, have long-term benefits in infants. 340 
 341 
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Tables 458 
 459 
Table 1: Baseline characteristics of study participants 460 
 461 
Category, characteristics Total study 
participants 
(N=734) 
Standard 
IPTp-SP  
(N=367) 
CSST/IPTp-
SP  
(N=367) 
P value 
Maternal characteristics 
Ageyears, MeanSD 26.4±6.2 26.0±6.2 26.7±6.2 .139 
Gravidityno. (%)    .674 
Primigravid 132 (18.0) 68 (18.5) 64 (17.4)  
Secundigravid 117 (15.9) 62 (16.9) 55 (15.0)  
Multigravid 485 (66.1) 237 (64.6) 248 (67.6)  
SP doses uptake, MeanSD 2.68±0.97 2.64 ±0.98 2.72±0.97  .236 
Total maternal peripheral infections detected by 
RDT* no.(%) 
159 (21.7) 50 (13.6) 109 (29.7) < .001 
Maternal peripheral infection at deliver by qPCR 
(MPI)**no. (%) 
152 (21.3) 84 (23.7) 68 (18.9) .119 
Placental malaria (PM)**no.(%)     
 21 
By qPCR  160 (22.8) 86 (24.4) 74 (21.3) .328 
By histology (acute, chronic, past infections) 447 (67.3) 215 (67.7) 232 (67.1) .878 
Gestational age at deliveryno. (%)    .199 
Pre-term delivery (28-36 weeks) 31 (4.2) 12 (3.3) 19 (5.2)  
Term delivery (>36 weeks) 703 (95.8) 355 (96.7) 348 (94.8)  
Insecticide treated net (ITN) useno. (%) 574 (78.2) 278 (75.7) 296 (80.7) .108 
Infant characteristics 
Sexno. (%)    .301 
Male 356 (48.5) 171 (46.6) 185 (50.4)  
Female 378 (51.5) 196 (53.4) 182 (49.6)  
Birth seasonno. (%)    .254 
High-transmission (July-December)  455 (62.0) 235 (64.0) 220 (59.9)  
Low-transmission (January-June) 279 (38.0) 132 (36.0) 147(40.1)  
Birth weightg, MeanSD 3012.7±422.2 2984.8±411.1 3040.6±431.7 .073 
Low birth weight (<2500) no. (%) 60 (8.2) 35 (9.5) 25 (6.8) .178 
NOTE. IPTp-SP, Intermittent Preventive Treatment during pregnancy with Sulfadoxine-Pyrimethamine; 
CSST/IPTp-SP, community-based scheduled screening and treatment of malaria during pregnancy with artemether-
lumefantrine plus standard IPTp-SP for malaria in pregnancy prevention and control; SD, Standard Deviation; g, 
gram. *Positive RDT cases diagnosed (at home visits (CSST/IPTp-SP arm)) and unscheduled visits (both IPTp-SP 
and CSST/IPTp-SP arms)) and confirmed by light microscopy. ** Missing: MPI detected by qPCR (N=713): 
Standard IPTp-SP =353, CSST/IPTp-SP=359; PM detected by qPCR (N=701): Standard IPTp-SP =353, 
CSST/IPTp-SP= 348; PM detected by histology (N=664): Standard IPTp-SP=318, CSST/IPTp-SP= 346; CM 
(N=703): Standard IPTp-SP=352, CSST/IPTp-SP=351.  
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 471 
Table 2: Effect of CSST/IPTp-SP on time-to-first clinical malaria episode by Cox 472 
proportional hazards analysis 473 
 474 
Characteristic Risk factor Unadjusted Adjusted* 
HR (95% CI) P value HR (95% CI) P value 
Overall cohort analysis 
MiP Intervention strategy Standard IPTp-SP  1  1  
 CSST/IPTp-SP  0.90 (0.75-1.09) .293 0.88 (0.73-1.07)  .205 
Gravidity Multigravid 1  1  
 Secundigravid 1.25 (0.97-1.61) .081 1.22 (0.94-1.56) .129 
 Primigravid 0.98 (0.75-1.28) .863 0.97 (0.75-1.27) .851 
Mother’s age >30 1    
 21-30 1.07 (0.85-1.35) .572   
 ≤20 1.03 (0.77-1.36) .856   
ITN use No 1    
 Yes 1.10 (0.85-1.44)  .462   
Birth season Low-transmission 1  1  
 High-transmission 0.69 (0.57-0.84) .001 0.69 (0.56-0.83)  .001 
Newborn sex Male 1    
 Female 0.90 (0.75-1.09) .284   
 23 
Stratified analysis (CSST/IPTp-SP vs standard IPTp-SP (ref)) 
Birth season Low-transmission 0.74 (0.55-0.99) .047   
 High-transmission 0.97 (0.76-1.25) .846   
NOTE. MiP, malaria in pregnancy; ITN, insecticide treated net; HR, hazard ratio; CI, confidence interval 
*Adjusted by variables that showed a P value < .1 in univariate analysis 
 475 
 476 
Table 3. Cox proportional analysis assessing the effect of prenatal malaria exposure on time 477 
to first clinical malaria episode 478 
 479 
Characteristic Risk factor Unadjusted Adjusted* 
HR (95% CI) P value HR (95% CI) P value 
Prenatal malaria exposure Non-infected mothers 1  1  
 Infected mothers 1.56 (1.09-2.23) .016 1.62 (1.12-2.32) .009 
 Past PM mothers 1.39 (1.04-1.86)  .026 1.42 (1.06-1.91) .020 
 Active PM mothers 1.12 (0.78-1.61)  .550 1.30 (0.89-1.91) .177 
LBW No 1  1  
 Yes 1.55 (1.13-2.13) .007 1.55 (1.10-2.18) .011 
Gravidity Multigravid 1  1  
 Secundigravid 1.25 (0.97-1.61) .081 1.13 (0.86-1.47) .384 
 Primigravid 0.98 (0.75-1.27) .863 0.97 (0.73-1.30) .865 
Mother’s age >30 1    
 21-30 1.07 (0.85-1.35) .572   
 ≤20 1.03 (0.77-1.36) .856   
Birth season Low-transmission 1    
 High-transmission 0.69 (0.57-0.84) .001 0.69 (0.56-0.86) .001 
Newborn sex Male 1    
 24 
 Female 0.90 (0.75-1.09) .284   
ITN use No 1    
 Yes 1.10 (0.85-1.44)  .462   
NOTE. PM, placental malaria; ITN, insecticide treated net; LBW, low birth weight; CI, confidence interval; HR, 
hazard ratio. *Adjusted by variables that showed a P value < .1 in univariate analyses. 
 480 
 481 
 482 
Table 4:  Effect of CSST/IPTp-SP on clinical malaria incidence during the first 12 months 483 
of life by Poisson regression analysis 484 
 485 
Characteristic Risk factor Univariate  Multivariate*  
IRR (95% CI) P value IRR (95% CI) P value 
MiP preventive strategy Standard IPTp-SP  1  1  
 CSST/IPTp-SP 0.94 (0.82-1.10) .479 0.95 (0.82-1.10) .459 
Gravidity  Multigravid 1    
 Secundigravid 1.11 (0.91-1.35) .291   
 Primigravid 0.97 (0.78-1.19) .756   
Mother’s age >30 1    
 21-30 1.01 (0.84-1.20) .932   
 ≤20 0.97 (0.78-1.20) .763   
ITN use No 1    
 Yes 0.99 (0.83-1.18) .892   
Birth season Low-transmission 1  1  
 High-transmission 0.88 (0.75-1.02) .091 0.91 (0.79-1.06) .229 
Newborn sex Male 1    
 Female 0.98 (0.85- 1.14) .811   
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NOTE. MiP, malaria in pregnancy; ITN, insecticide treated net; IRR, incidence rate ratio; CI, confidence interval 
* Adjusted by variables that showed a P value < .1 in univariate analysis. 
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Table 5: Stratified analyses of the effect of CSST/IPTp-SP on the incidence of NMFs 492 
 493 
CSST/IPTp-SP vs IPTp-SP (ref) Unadjusted 
stratum-specific 
IRR (95% CI) 
P value Adjusted* 
stratum-specific 
IRR (95% CI) 
P value 
By birth season Low-transmission  1.00 (0.76-1.32) .977 1.02 (0.77-1.34) .887 
 High-transmission 0.80 (0.64-0.99) .039 0.79 (0.64-0.98) .031 
By gravidity Multigravid 0.81 (0.65-0.99) .042 0.78 (0.63-0.97) .027 
 Secundigravid 0.82 (0.55-1.20) .281 0.83 (0.56-1.23) .357 
 Primigravid 1.35 (0.92-1.99) .130 1.35 (0.92-1.99) .119 
NOTE. IRR, incidence rate ratio; ref, reference 
*Adjusted by gravidity or by birth season 
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 505 
Figures 506 
 507 
Figure 1: Study flow diagram. Infants born from pregnant women participating in a randomized-508 
cluster trial (CSST/IPTp-SP vs standard IPTp) [14] were recruited into the study at birth and 509 
followed-up until 12 months of age. Lost to follow-up are infants who did not complete the 12-510 
months follow-up. They were considered as censored observations at the time of the last visit in 511 
survival analysis. Neonatal deaths and twins were excluded from the analysis. *Not included in the 512 
survival analysis. ** Included in the survival analysis. 513 
 514 
Figure 2: Kaplan-Meier survival curves for time-to-first clinical malaria episode during the 515 
first year of life according to MiP prevention strategy by birth season. Infants born during 516 
malaria low transmission season (A) and born during malaria high transmission season (B) were 517 
followed-up for 12 months. 518 
 519 
